pancreatic cancer Archives -

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer,

Amgen eyes pancreatic cancer use for its pathfinder KRAS drug

https://pharmaphorum.com/news/amgen-eyes-pancreatic-cancer-use-for-kras-drug/

News/ News/ Oncology

RedX Pharma CEO focuses on pipeline that found Lilly’s rising star

Richard Staines Oncology, pancreatic cancer, R&D, Redx Pharma 0 Comment

Back in 2017, the UK biotech RedX Pharma had to sell its prized asset after administrators stepped in

RedX Pharma CEO focuses on pipeline that found Lilly’s rising star

https://pharmaphorum.com/news/redx-looks-to-keep-pipeline-assets-after/

Digital/ News/ News/ News/ Oncology

AI health record scanning could identify pancreatic cancer early

Phil Taylor artificial intelligence, diagnosis, digital, Oncology, pancreatic cancer 0 Comment

Artificial intelligence (AI) could hold the key to identifying people at risk of pancreatic cancer early, allowing them

AI health record scanning could identify pancreatic cancer early

https://pharmaphorum.com/news/ai-health-record-scanning-could-identify-pancreatic-cancer-early/

Oncology/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

‘More people will die from pancreatic cancer’: How COVID-19 is diverting resources and costing lives

Amanda Barrell coronavirus, COVID-19, pancreatic cancer 0 Comment

More people with pancreatic cancer will die from the disease if the COVID-19 crisis continues to demand the

‘More people will die from pancreatic cancer’: How COVID-19 is diverting resources and costing lives

https://pharmaphorum.com/views-analysis-oncology/more-people-will-die-from-pancreatic-cancer-how-covid-19-is-diverting-resources-and-costing-lives/

News/ News/ Oncology

AZ, Merck add pancreatic cancer to Lynparza’s growing use list

Phil Taylor AstraZeneca, Lynparza, Merck & Co, pancreatic cancer, PARP inhibitor 0 Comment

AstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for

AZ, Merck add pancreatic cancer to Lynparza’s growing use list

https://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/

Market Access/ News/ News/ News/ Oncology/ Top stories

AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancer

Phil Taylor AstraZeneca, Lynparza, Merck & Co, Oncology, pancreatic cancer, PARP inhibitor 0 Comment

AstraZeneca and Merck & Co are closer to a new use for their PARP inhibitor Lynparza in pancreatic

AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancer

https://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/

News/ News/ Oncology

Halozyme abandons cancer R&D as lead drug failed

Phil Taylor Enhanze, Halozyme, Oncology, pancreatic cancer 0 Comment

US biotech Halozyme has been forced to cut more than half its workforce and exit cancer R&D after

Halozyme abandons cancer R&D as lead drug failed

https://pharmaphorum.com/news/halozyme-abandons-cancer-rd-as-lead-drug-failed/

News/ News/ Oncology/ Top stories

Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trial

Richard Staines cancer, Eli Lilly, pancreatic cancer 0 Comment

Eli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a

Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trial

https://pharmaphorum.com/news/lillys-1-6bn-cancer-drug-draws-blank-in-pancreatic-cancer-trial/

ASCO 2019 and the future of oncology/ News/ News/ Oncology

AZ/Merck & Co wow ASCO with pancreatic cancer data

Richard Staines AstraZeneca, cancer, Merck & Co, pancreatic cancer 0 Comment

Finding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the

AZ/Merck & Co wow ASCO with pancreatic cancer data

https://pharmaphorum.com/news/az-merck-co-wow-asco-with-pancreatic-cancer-data/

Trending

pancreatic cancer

Login